Elicio Therapeutics Valuation
| ELTX Stock | 8.23 0.01 0.12% |
At this time, the firm appears to be fairly valued. Elicio Therapeutics shows a prevailing Real Value of USD8.08 per share. The current price of the firm is USD8.23. Our model computes the value of Elicio Therapeutics from reviewing the firm fundamentals such as Shares Owned By Insiders of 28.62 %, current valuation of 97.66 M, and Number Of Shares Shorted of 145.79 K as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Elicio Therapeutics' valuation include:
Fairly Valued
Today
Please note that Elicio Therapeutics' price fluctuation is slightly risky at this time. Calculation of the real value of Elicio Therapeutics is based on 3 months time horizon. Increasing Elicio Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Elicio Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Elicio Stock. However, Elicio Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 8.23 | Real 8.08 | Target 9.5 | Hype 9.1 | Naive 7.87 |
The intrinsic value of Elicio Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Elicio Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Elicio Therapeutics helps investors to forecast how Elicio stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Elicio Therapeutics more accurately as focusing exclusively on Elicio Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Elicio Therapeutics' intrinsic value based on its ongoing forecasts of Elicio Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Elicio Therapeutics' closest peers.
Elicio Therapeutics Cash |
|
Elicio Valuation Trend
Analysing the historical paterns of Elicio Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Elicio Therapeutics over time and is usually enough for investors to make rational market timing decisions.
Elicio Therapeutics Total Value Analysis
Elicio Therapeutics is currently anticipated to have valuation of 97.66 M with market capitalization of 99.32 M, debt of 6.92 M, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Elicio Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
97.66 M | 99.32 M | 6.92 M |
Elicio Therapeutics Asset Utilization
One of the ways to look at asset utilization of Elicio is to check how much profit was generated for every dollar of assets it reports. Elicio Therapeutics shows a negative utilization of assets of -0.74 percent, losing USD0.00737 for each dollar of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Elicio Therapeutics shows how discouraging it operates for each dollar spent on its assets.Elicio Therapeutics Ownership Allocation
The market capitalization of Elicio Therapeutics is USD99.32 Million. Elicio Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Elicio Therapeutics Profitability Analysis
Net Loss for the year was (35.2 M) with profit before overhead, payroll, taxes, and interest of 0.About Elicio Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Elicio Therapeutics. We calculate exposure to Elicio Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Elicio Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -1.1 M | -1 M | |
| Pretax Profit Margin | (1.07) | (1.13) | |
| Operating Profit Margin | (1.03) | (1.09) | |
| Net Loss | (1.07) | (1.13) | |
| Gross Profit Margin | 0.86 | 0.46 |
Elicio Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 5.1 M |
Elicio Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Elicio Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Elicio we look at many different elements of the entity such as Elicio's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Elicio Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Elicio Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Elicio Therapeutics' worth.Additional Tools for Elicio Stock Analysis
When running Elicio Therapeutics' price analysis, check to measure Elicio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elicio Therapeutics is operating at the current time. Most of Elicio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Elicio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elicio Therapeutics' price. Additionally, you may evaluate how the addition of Elicio Therapeutics to your portfolios can decrease your overall portfolio volatility.